Prof William Pao to head Roche oncology unit
This article was originally published in Scrip
Executive Summary
Swiss pharma Roche has named professor of medicine at Vanderbilt University Medical Center, William Pao, global head of its oncology disease and translational unit – effective 1 May 2014. He will be based in Basel, Switzerland and will report to Dr John Reed global head of Roche Pharma Research and Early Development (pRED). Professor Pao is currently an advisor to the National Cancer Institute (NCI), American Association for Cancer Research (AACR), American Society for Clinical Oncology (ASCO), and other professional societies, while also serving on the editorial boards of several medical research journals including Cancer Research, Clinical Cancer Research, and Journal of Clinical Oncology. Furthermore, Professor Pao is a co-founder of MyCancerGenome, a web-based tool for clinical decision support to enable a genetically informed approach to cancer medicine. At Roche he will be responsible for leading the company's discovery, translational medicine and early development of innovative oncology medicines.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.